Zhao Yiming , Zheng Dongxue , Cheng Ran , Xu Xin , Lian Fengmei , Tong Xiaolin , Liu Xinmin
{"title":"加味芝白地黄汤治疗多囊卵巢综合征雄激素过多症的剂量效应分析","authors":"Zhao Yiming , Zheng Dongxue , Cheng Ran , Xu Xin , Lian Fengmei , Tong Xiaolin , Liu Xinmin","doi":"10.1016/j.jtcm.2018.03.002","DOIUrl":null,"url":null,"abstract":"<div><h3>OBJECTIVE</h3><p>To observe the efficacy and safety of different dosages of modified Zhibaidihuang decoction (MZBDD) on polycystic ovary syndrome (PCOS) hyperandrogenism (HA) patients.</p></div><div><h3>METHODS</h3><p>Ninety PCOS HA patients and 30 infertile patients due to tubal factor were selected. Ninety PCOS HA patients were randomly divided into three groups: low dosage group (LDG), medium dosage group (MDG) and high dosage group (HDG) and infertile patients were selected as normal control group (NCG). PCOS HA patients were treated with different dosage of MZBDD for 4 weeks. For HA patients, serum total testosterone (T), estrodial (E<sub>2</sub>), follicle stimulating hormone (FSH), luteinizing hormone (LH), prolatin (PRL), alanine aminotransferase (AST), aspartate amino transferase (AST) were determined before and after treatment, while acne scores (Rosenfield) were signed. Basal body temperatures (BBT) were asked to be measured every day. And for the else, T, E<sub>2</sub>, FSH, LH, PRL, AST, and AST were determined before treatment.</p></div><div><h3>RESULTS</h3><p>Totally 111 patients completed the clinical research. There were no differences among the four groups on serum T before treatment (<em>P</em> = 0.221). Serum T concentration of both MDG and HDG after treatment significantly were lower than that of before treatment (<em>P</em> = 0.039, <em>P</em> = 0.000), while there was no obvious difference in LDG (<em>P</em> = 0.829). Serum T concentration of both MDG and HDG were significantly lower than that of LDG after treatment (<em>P</em> = 0.048, <em>P</em> = 0.006). To compared with before treatment, there were no differences in Serum FSH, LH, E<sub>2</sub>, P and PRL among the three groups (LDG, MDG, HDG) (as for FSH, <em>P</em> = 0.136, <em>P</em> = 0.503, <em>P</em> = 0.062; as for LH, <em>P</em> = 0.473, <em>P</em> = 0.513, <em>P</em> = 0.096; as for E<sub>2</sub>, <em>P</em> = 0.206, <em>P</em> = 0.927, <em>P</em> = 0.076; as for PRL, <em>P</em> = 0.120, <em>P</em> = 0.903, <em>P</em> = 0.407, as for P, <em>P</em> = 0.308, <em>P</em> = 0.866, <em>P</em> = 0480). Acne scores of all the three groups were obviously lower than that of before treatment (<em>P</em> = 0.031; <em>P</em> = 0.033; <em>P</em> = 0.002). 39.5% of the patients had biphasic BBT, but there were no differences among the three groups (<em>P</em> = 0.510). There were no differences with ALT and AST between after and before treatment among the three groups (LDG, MDG, HDG) (as for ALT, <em>P</em> = 0.742, <em>P</em> = 0.383, <em>P</em> = 0.053; as for AST, <em>P</em> = 0.732, <em>P</em> = 0.519, <em>P</em> = 0.120).</p></div><div><h3>CONCLUSION</h3><p>Different dosage of MZBDD has dose-effect relationship in treating PCOS HA.</p></div>","PeriodicalId":17513,"journal":{"name":"Journal of Traditional Chinese Medicine","volume":"38 2","pages":"Pages 280-286"},"PeriodicalIF":2.0000,"publicationDate":"2018-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jtcm.2018.03.002","citationCount":"2","resultStr":"{\"title\":\"Dose-effect analysis of treatment by modified Zhibaidihuang decoction on polycystic ovary syndrome hyperandrogenism\",\"authors\":\"Zhao Yiming , Zheng Dongxue , Cheng Ran , Xu Xin , Lian Fengmei , Tong Xiaolin , Liu Xinmin\",\"doi\":\"10.1016/j.jtcm.2018.03.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>OBJECTIVE</h3><p>To observe the efficacy and safety of different dosages of modified Zhibaidihuang decoction (MZBDD) on polycystic ovary syndrome (PCOS) hyperandrogenism (HA) patients.</p></div><div><h3>METHODS</h3><p>Ninety PCOS HA patients and 30 infertile patients due to tubal factor were selected. Ninety PCOS HA patients were randomly divided into three groups: low dosage group (LDG), medium dosage group (MDG) and high dosage group (HDG) and infertile patients were selected as normal control group (NCG). PCOS HA patients were treated with different dosage of MZBDD for 4 weeks. For HA patients, serum total testosterone (T), estrodial (E<sub>2</sub>), follicle stimulating hormone (FSH), luteinizing hormone (LH), prolatin (PRL), alanine aminotransferase (AST), aspartate amino transferase (AST) were determined before and after treatment, while acne scores (Rosenfield) were signed. Basal body temperatures (BBT) were asked to be measured every day. And for the else, T, E<sub>2</sub>, FSH, LH, PRL, AST, and AST were determined before treatment.</p></div><div><h3>RESULTS</h3><p>Totally 111 patients completed the clinical research. There were no differences among the four groups on serum T before treatment (<em>P</em> = 0.221). Serum T concentration of both MDG and HDG after treatment significantly were lower than that of before treatment (<em>P</em> = 0.039, <em>P</em> = 0.000), while there was no obvious difference in LDG (<em>P</em> = 0.829). Serum T concentration of both MDG and HDG were significantly lower than that of LDG after treatment (<em>P</em> = 0.048, <em>P</em> = 0.006). To compared with before treatment, there were no differences in Serum FSH, LH, E<sub>2</sub>, P and PRL among the three groups (LDG, MDG, HDG) (as for FSH, <em>P</em> = 0.136, <em>P</em> = 0.503, <em>P</em> = 0.062; as for LH, <em>P</em> = 0.473, <em>P</em> = 0.513, <em>P</em> = 0.096; as for E<sub>2</sub>, <em>P</em> = 0.206, <em>P</em> = 0.927, <em>P</em> = 0.076; as for PRL, <em>P</em> = 0.120, <em>P</em> = 0.903, <em>P</em> = 0.407, as for P, <em>P</em> = 0.308, <em>P</em> = 0.866, <em>P</em> = 0480). Acne scores of all the three groups were obviously lower than that of before treatment (<em>P</em> = 0.031; <em>P</em> = 0.033; <em>P</em> = 0.002). 39.5% of the patients had biphasic BBT, but there were no differences among the three groups (<em>P</em> = 0.510). There were no differences with ALT and AST between after and before treatment among the three groups (LDG, MDG, HDG) (as for ALT, <em>P</em> = 0.742, <em>P</em> = 0.383, <em>P</em> = 0.053; as for AST, <em>P</em> = 0.732, <em>P</em> = 0.519, <em>P</em> = 0.120).</p></div><div><h3>CONCLUSION</h3><p>Different dosage of MZBDD has dose-effect relationship in treating PCOS HA.</p></div>\",\"PeriodicalId\":17513,\"journal\":{\"name\":\"Journal of Traditional Chinese Medicine\",\"volume\":\"38 2\",\"pages\":\"Pages 280-286\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2018-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.jtcm.2018.03.002\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Traditional Chinese Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0254627218302474\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"INTEGRATIVE & COMPLEMENTARY MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Traditional Chinese Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0254627218302474","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}
引用次数: 2
摘要
目的观察不同剂量栀白地黄汤加味治疗多囊卵巢综合征(PCOS)高雄激素症(HA)的疗效和安全性。方法选择90例PCOS HA患者和30例输卵管因素导致的不孕患者。90例PCOS HA患者随机分为低剂量组(LDG)、中剂量组(MDG)、高剂量组(HDG) 3组,选取不育患者作为正常对照组(NCG)。PCOS HA患者采用不同剂量的MZBDD治疗4周。HA患者治疗前后测定血清总睾酮(T)、雌二醇(E2)、促卵泡激素(FSH)、促黄体生成素(LH)、催乳素(PRL)、丙氨酸转氨酶(AST)、天冬氨酸转氨酶(AST),并标记痤疮评分(Rosenfield)。要求每天测量基础体温(BBT)。治疗前检测T、E2、FSH、LH、PRL、AST、AST。结果共111例患者完成临床研究。四组患者治疗前血清T水平比较,差异无统计学意义(P = 0.221)。治疗后MDG、HDG血清T浓度均显著低于治疗前(P = 0.039, P = 0.000), LDG无明显差异(P = 0.829)。治疗后MDG和HDG血清T浓度均显著低于LDG (P = 0.048, P = 0.006)。三组(LDG、MDG、HDG)患者血清FSH、LH、E2、P、PRL与治疗前比较,差异均无统计学意义(FSH, P = 0.136、P = 0.503、P = 0.062;LH, P = 0.473, P = 0.513, P = 0.096;E2, P = 0.206, P = 0.927, P = 0.076;PRL P = 0.120, P = 0.903, P = 0.407, P = 0.308, P = 0.866, P = 0480)。三组患者痤疮评分均显著低于治疗前(P = 0.031;P = 0.033;P = 0.002)。39.5%的患者为双期BBT,但三组间差异无统计学意义(P = 0.510)。LDG、MDG、HDG三组患者治疗前后ALT、AST差异无统计学意义(ALT, P = 0.742, P = 0.383, P = 0.053;AST, P = 0.732, P = 0.519, P = 0.120)。结论不同剂量MZBDD治疗PCOS HA有剂量效应关系。
Dose-effect analysis of treatment by modified Zhibaidihuang decoction on polycystic ovary syndrome hyperandrogenism
OBJECTIVE
To observe the efficacy and safety of different dosages of modified Zhibaidihuang decoction (MZBDD) on polycystic ovary syndrome (PCOS) hyperandrogenism (HA) patients.
METHODS
Ninety PCOS HA patients and 30 infertile patients due to tubal factor were selected. Ninety PCOS HA patients were randomly divided into three groups: low dosage group (LDG), medium dosage group (MDG) and high dosage group (HDG) and infertile patients were selected as normal control group (NCG). PCOS HA patients were treated with different dosage of MZBDD for 4 weeks. For HA patients, serum total testosterone (T), estrodial (E2), follicle stimulating hormone (FSH), luteinizing hormone (LH), prolatin (PRL), alanine aminotransferase (AST), aspartate amino transferase (AST) were determined before and after treatment, while acne scores (Rosenfield) were signed. Basal body temperatures (BBT) were asked to be measured every day. And for the else, T, E2, FSH, LH, PRL, AST, and AST were determined before treatment.
RESULTS
Totally 111 patients completed the clinical research. There were no differences among the four groups on serum T before treatment (P = 0.221). Serum T concentration of both MDG and HDG after treatment significantly were lower than that of before treatment (P = 0.039, P = 0.000), while there was no obvious difference in LDG (P = 0.829). Serum T concentration of both MDG and HDG were significantly lower than that of LDG after treatment (P = 0.048, P = 0.006). To compared with before treatment, there were no differences in Serum FSH, LH, E2, P and PRL among the three groups (LDG, MDG, HDG) (as for FSH, P = 0.136, P = 0.503, P = 0.062; as for LH, P = 0.473, P = 0.513, P = 0.096; as for E2, P = 0.206, P = 0.927, P = 0.076; as for PRL, P = 0.120, P = 0.903, P = 0.407, as for P, P = 0.308, P = 0.866, P = 0480). Acne scores of all the three groups were obviously lower than that of before treatment (P = 0.031; P = 0.033; P = 0.002). 39.5% of the patients had biphasic BBT, but there were no differences among the three groups (P = 0.510). There were no differences with ALT and AST between after and before treatment among the three groups (LDG, MDG, HDG) (as for ALT, P = 0.742, P = 0.383, P = 0.053; as for AST, P = 0.732, P = 0.519, P = 0.120).
CONCLUSION
Different dosage of MZBDD has dose-effect relationship in treating PCOS HA.
期刊介绍:
Journal of Traditional Chinese Medicine(JTCM) is devoted to clinical and theortical research on the use of acupuncture and Oriental medicine. The main columns include Clinical Observations, Basic Investigations, Reviews, Questions and Answers, an Expert''s Forum, and Discussions of Clinical Cases. Its key topics include acupuncture and electro-acupuncture, herbal medicine, homeopathy, masseotherapy, mind-body therapies, palliative care, and other CAM therapies.